QUÉBEC CITY, Jan. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Jacek Pinski, MD, PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, will present updated interim results from a Phase 1 clinical trial in prostate cancer with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone releasing hormone ("LHRH") analog. The presentation will take place on Thursday, February 2, 2012, during the American Society of Clinical Oncology Genitourinary Cancers Symposium which will be held February 2-4, 2012 in San Francisco.
Poster D3: "A Phase 1 trial of AEZS-108 in castration - and taxane-resistant prostate cancer ", S.V. Liu, A.V. Schally, T.B. Dorff, D.D. Tsao-Wei, S.G. Groshen, S. Xiong, D. Hawes, D.I. Quinn, Y.C. Tai, N.L. Block, J. Engel, J. K. Pinski
Presenter: Jacek Pinski, MD, PhD
Session: General Poster Session A: Prostate Cancer
Date and time: Thursday, February 2, 2012, 11:45 a.m. - 1:15 p.m. (Pacific)
Venue: Golden Gate Hall, San Francisco Marriot Marquis
I am well aware that biotechs do poster presentations. Or more accurately, researchers do poster presentations, using biotechs' drugs.
But updated interim phase 1 results was such an underwhelming rubric, I assumed they must have something reasonably exciting. Oh, well.
You are right in that the real prize, in the short term, is the Feb. 14 update.
So maybe the action before the bell could get dicey today. This presentation isn't the ice ... ice maker but! it sure makes some investors feel good that AEZS-108 is behind door number two. Worst case is you've got to sit on the investment for a couple of years to get your money back from what's behind door number one. I'm letting it ride...
Press release should be out tomorrow morning.
After what is shaping up to be a fairly good day in the markets today. (European bourses up more than 1 percent.)
Should be a fun couple of days.